Sugi Predict

Sugi Predict / Compounds / SCHEMBL1138806

SCHEMBL1138806

SCHEMBL1138806

CC(C)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.71

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HINT1 P49773 6/20 0.71
▸ NT5E P21589 1/20 0.68
▸ GSK3A P49840 2/20 0.64
▸ RPS6KA3 P51812 2/20 0.64
▸ MAPK14 Q16539 2/20 0.64
▸ TGM2 P21980 1/20 0.63
▸ PNP P00491 1/20 0.61
▸ FUT5 Q11128 1/20 0.59
▸ IMPDH2 P12268 2/20 0.58
▸ IMPDH1 P20839 1/20 0.58
▸ KRAS P01116 5/20 0.57
▸ TAAR1 Q96RJ0 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27277386 0.91 HINT1 (0.59) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL17082332 0.89 HINT1 (0.67) HINT1NT5EGSK3ARPS6KA3MAPK14
2'-Beta-Methyl-Guanosine SCHEMBL14178410 0.89 HINT1 (0.75) HINT1NT5EGSK3ARPS6KA3MAPK14
2'-Beta-Methyl-Guanosine SCHEMBL383785 0.89 HINT1 (0.75) HINT1NT5EGSK3ARPS6KA3MAPK14
2'-Beta-Methyl-Guanosine SCHEMBL116165 0.89 HINT1 (0.75) HINT1NT5EGSK3ARPS6KA3MAPK14
2'-Beta-Methyl-Guanosine SCHEMBL15338533 0.89 HINT1 (0.75) HINT1NT5EGSK3ARPS6KA3MAPK14
2'-Beta-Methyl-Guanosine SCHEMBL11965261 0.89 HINT1 (0.75) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL5180584 0.89 HINT1 (0.69) HINT1NT5EGSK3ARPS6KA3MAPK14
SCHEMBL1611244 0.89 HINT1 (0.77) HINT1NT5EGSK3ARPS6KA3MAPK14
2'-Beta-Methyl-Guanosine SCHEMBL5972612 0.88 HINT1 (0.73) HINT1NT5EGSK3ARPS6KA3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220088097-A1 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF SATOR THERAPEUTICS 2022-03-24 — — US claimed
EP-0948256-A4 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA UNIV WASHINGTON (US) 2007-10-24 — — EP claimed
US-6887707-B2 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA UNIVERSITY OF WASHINGTON (US) 2005-05-03 — — US claimed
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-26 — — US claimed
EP-0948256-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1999-10-13 — — EP claimed
WO-1998018324-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1998-05-07 — — WO claimed
US-12357664-B2 Optimized oncolytic viruses and uses thereof SATOR THERAPEUTICS (US) 2025-07-15 — — US disclosed
US-20240052357-A1 AUTONOMOUS INDUCIBLE DIRECTED EVOLUTION OF COMPLEX PATHWAYS NORTH CAROLINA STATE UNIVERSITY 2024-02-15 — — US disclosed
US-20220088097-A1 OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF SATOR THERAPEUTICS 2022-03-24 — — US disclosed
EP-1576154-B8 IN VIVO AFFINITY MATURATION SCHEME ANAPTYSBIO INC (US) 2011-04-13 — — EP disclosed
EP-1576154-B1 IN VIVO AFFINITY MATURATION SCHEME QUINTAIN CONSULTING PTY LTD (AU) 2011-02-23 — — EP disclosed
US-20090311710-A1 MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES COIA GREGORY 2009-12-17 — — US disclosed
WO-2009043096-A1 IMPROVED METHOD FOR MUTAGENESIS ARANA THERAPEUTICS (VIC) PTY LTD (AU) 2009-04-09 — — WO disclosed
WO-2004039995-A1 MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES EVOGENIX PTY LTD (AU) 2004-05-13 — — WO disclosed
US-20030148267-A1 Screening assay for hepatitis C virus antiviral agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-08-07 — — US disclosed
US-20030130226-A1 Inhibition of viruses MEDICAL RESEARCH COUNCIL 2003-07-10 — — US disclosed
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-26 — — US disclosed
WO-2003039450-A2 IMPROVEMENTS IN OR RELATING TO INHIBITION OF VIRUSES MEDICAL RESEARCH COUNCIL (GB) 2003-05-15 — — WO disclosed
EP-0948256-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1999-10-13 — — EP disclosed
WO-1998018324-A1 INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA THE UNIVERSITY OF WASHINGTON (US) 1998-05-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119764-A1 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA SAMHD1, BCDIN3D, DCTD HINT1 280/4885NT5E 846/4885GSK3A 1640/4885
US-20030130226-A1 Inhibition of viruses HNRNPA1, RNASEH1, RNASE1 HINT1 1171/4885NT5E 878/4885GSK3A 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.